TEST:

MSK-IMPACT

After adjusting for potential confounders, the prognosis of patients with liver metastases remained an independent risk factor for ICIs (HR: 1.67, 95% CI: 1.31-2.12). Liver metastasis may be an independent risk factor for advanced solid tumors treated with ICIs.

These data support RRAS Q87L and RRAS2 Q72L as bona fide lung cancer drivers and nominate RRAS/RRAS2-mutant tumors as candidates for pan-RAS-targeted therapeutics. Our findings provide a biologic rationale and preclinical evidence to inform molecular testing paradigms and to prioritize enrollment of patients with RRAS/RRAS2-mutant NSCLC into future clinical trials of pan-RAS inhibitors.

P1, N=22, Active, not recruiting, National Cancer Institute (NCI) | N=85 --> 22 | Trial completion date: Jun 2026 --> Nov 2026 | Trial primary completion date: Jun 2026 --> Nov 2025

MTAP dels frequently co-occur with oncogenic driver alterations and can develop at time of osimertinib resistance. A patient with oncogenic driver-positive, MTAP-del NSCLC had a partial response to PRMT5 inhibitor treatment. This work could inform future trials of PRMT5 and MAT2A inhibitors.

Contemporary thyroid cancer BrM outcomes are dependent on primary malignancy histology and may benefit from further molecular profiling.

This sex-informed, spatially validated score provides a reproducible and biologically interpretable framework for transcriptomic risk stratification in gynecologic cancers. By capturing immune-evasive and aggressive tumor states, it might inform biomarker-guided clinical trials and support context-appropriate implementation of precision oncology strategies.

Compared to previous reports, Japanese ES cases showed lower STAG2 and higher TP53 mutation frequencies. CDKN2A and CDKN2B deletions may serve as prognostic biomarkers indicating unfavorable outcomes.

This novel RINH model offers a robust tool for risk stratification in mHSPC patients, capable of personalizing therapeutic strategies. However, external validation in multi-center, prospective cohorts is an essential next step before its consideration as a clinical decision support tool.

P2, N=13, Recruiting, Memorial Sloan Kettering Cancer Center | Trial primary completion date: Nov 2025 --> Nov 2026 | N=25 --> 13 | Trial completion date: Nov 2025 --> Nov 2026

These findings establish FGFR1 alterations as an alternative oncogenic driver in a subset of FOXL2-wildtype aGCTs. From a diagnostic standpoint, the absence of FOXL2 p.C134W mutation does not exclude the diagnosis of aGCT when the morphology and immunoprofile are characteristic.

Exercise was not associated with CH burden but does reduce excess ACM of CH in patients with cancer. Further research is needed to investigate the exercise-CH relationship in cancer and other populations. Trial Registration Clinical trials.gov number: NCT03996239.

"We are proud to continue our expansion in the Middle East through our collaboration with National Reference Laboratory (NRL), a leader in pathology and one of the largest CAP-accredited laboratory networks in the region.This partnership reflects a shared commitment to advancing data-driven cancer care and expanding access to genomic insights across the UAE.As part of this collaboration, NRL has adopted MSK-IMPACT® powered with SOPHiA DDM™ — a decentralized, comprehensive genomic profiling solution co-developed with Memorial Sloan Kettering Cancer Center."